<DOC>
	<DOCNO>NCT00543634</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy new tablet formulation Premarin速/medroxyprogesterone ( MPA ) .</brief_summary>
	<brief_title>Study Comparing Premarin速/MPA , PREMPRO速 Provera速 Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Healthy postmenopausal woman age 35 70 year spontaneous surgical amenorrhea BMI range 18 35 kg/m2 History presence hypertension ( &gt; 139 mm Hg systolic &gt; 89 mm Hg diastolic ) History drug allergy , particularly conjugate estrogen ( CE ) selective estrogen receptor modulators ( SERMs ) Use prescription investigational drug within 30 day test article administration</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>